SPIN Award Program 2015
The SPIN (Scientific Progress – Immunoglobulins in Neurology) Awards are part of the Grifols Scientific Awards program, which is committed to promoting scientific research as the cornerstone of a process that will lead to better health and quality of life for patients.
The SPIN Awards Program supports the development and testing of innovative ideas and hypotheses in the field of immunoglobulin research in neurology. It was launched in 2008 under its former name, eSPIN (European Scientific Progress – Immunoglobulins in Neurology). As of this year, the scope of the SPIN Awards has been extended and now invites applications from around the globe.
The first winner of the new, global 2015 SPIN Award is: Krista Kuitwaard, MD, from The Netherlands.
Her project "Genetic biomarkers associated with IVIg treatment response or dependency in CIDP" aims to answer a relevant and pertinent question, which may have a positive impact on the therapy of chronic inflammatory demyelinating polyneuropathy (CIDP). The project has the potential to improve the treatment in patients suffering from this rare neurological condition and, therewith, convinced the international jury to award Dr. Kuitwaard with a research grant for funding of the proposed project for one year.
About the SPIN Award Program
The SPIN Award Program offers a prize of 50,000 euros for the proposal that best matches the program's objectives:
- To develop novel concepts in immunoglobulin research in neurology
- To encourage the discovery of beneficial immunoglobulin applications in neurological disorders
- To promote research on novel therapeutic options for patients with neurological conditions.
The application process for the 2016 cycle commences on August 1, 2015, and will remain open until January 31, 2016.
Applicants should submit a letter of intent outlining the aims of their research project. The Review Committee, which is comprised of experts from healthcare and research, will then decide upon a short list of candidates to submit a full proposal. The full proposals in which the projects are described in detail are then evaluated before a final selection is made.
The program is open to all young clinicians and researchers up to 40 years old who are working in hospitals and/or scientific research centers, independently or as a team. Profit-oriented projects and projects with the participation of pharmaceutical companies will not be considered.
More information regarding the SPIN Awards, candidate requirements, and the application process can be found at: www.spin-awards.com
About Grifols, 75th Anniversary of improving pleople's health
Grifols is a global healthcare company founded in 1940. In 2015 Grifols celebrates its 75th Anniversary of improving people's health and well being through the development of life-saving plasma medicines, diagnostics systems, and hospital pharmacy products.
The company is present in more than 100 countries worldwide and is headquartered in Barcelona, Spain. Grifols is a leader in plasma collection with a network of 150 plasma donor centers in the U.S., and a leading producer of plasma-derived biological medicines. The company also provides a comprehensive range of transfusion medicine, hemostasis, and immunoassay solutions for clinical laboratories, blood banks and transfusion centers, and is a recognized leader in transfusion medicine.
In 2014, sales exceeded 3,350 million euros with a headcount close to 14,000 employees. Grifols demonstrates its commitment to advancing healthcare by allocating a significant portion of its annual income to R&D.
The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Its non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ via ADRs (NASDAQ: GRFS). For more information visit www.grifols.com
Grifols Deutschland GmbH
Lyoner Strasse 15
60528 Frankfurt am Main
Tel: (49) (69) 660593 100
Fax: (49) (69) 660593 110